ArticleJournal of surgical oncology2020
Survival benefit of lymphadenectomy for gallbladder cancer based on the therapeutic index: An analysis of the US extrahepatic biliary malignancy consortium.
Article in Journal of surgical oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Is Extended Lymphadenectomy in Biliary Tract Cancers Justified? A Retrospective Comparative Study of Gallbladder Cancer, Perihilar and Intrahepatic Cholangiocarcinoma.Annals of surgical oncology · 2026Article
- Lymph Node Dissection in Biliary Tract Cancers: Time for a Rethink?Annals of surgical oncology · 2026Article
- Optimizing Lymph Node Staging in Gallbladder Cancer: A Cutoff of 11 Nodes for Accurate Staging and Improved Survival.Journal of hepato-biliary-pancreatic sciences · 2026Article
- Gallbladder carcinoma in Brazil: Clinicopathological profile and survival outcomes from a high-volume cancer center.World journal of gastroenterology · 2026Article
- Facility Type Predicts Completeness of Oncologic Resection and Survival in Biliary Tract Cancers.Journal of gastrointestinal cancer · 2026Article
- Selective lymph node dissection in intrahepatic cholangiocarcinoma and combined hepatocellular cholangiocarcinoma may not impair oncological outcomes: a single-center retrospective cohort study.World journal of surgical oncology · 2025Article
- Recent Trends in Surgical Strategies of Early-Stage Gallbladder Cancer: A Narrative Review.Journal of clinical medicine · 2025Review
- Prognostic Factors and Treatment Outcomes in Gallbladder Cancer Patients Undergoing Curative Surgery: A Multicenter Retrospective Cohort Study.Current oncology (Toronto, Ont.) · 2025Article
- Clinical diagnosis and treatment of 37 cases of gallbladder neuroendocrine carcinoma.World journal of surgical oncology · 2024Article
- Neoadjuvant Therapy for Extrahepatic Biliary Tract Cancer: A Propensity Score-Matched Survival Analysis.Journal of clinical medicine · 2023Article
- Gallbladder cancer: current and future treatment options.Frontiers in pharmacology · 2023Review
- Article
- Identification of publication characteristics and research trends in the management of gallbladder cancer.iLIVER · 2022Article
- Prediction of Early Recurrence After R0 Resection for Gallbladder Carcinoma of Stage T1b-T3.Cancer management and research · 2022Article
- Essential updates 2019/2020: Surgical treatment of gallbladder cancer.Annals of gastroenterological surgery · 2021Review
- Optimal extent of central lymphadenectomy for right-sided colon cancers: is lymphadenectomy beyond the superior mesenteric vein meaningful?Surgery today · 2021Article
- Survival benefit of lymphadenectomy for gallbladder cancer based on the therapeutic index: An analysis of the US extrahepatic biliary malignancy consortium.Journal of surgical oncology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
backgroundThe survival benefit of lymphadenectomy among patients with gallbladder cancer (GBC) remains poorly understood.
methodsPatients who underwent resection for GBC between 2000 and 2015 were identified from a US multi-institutional database. The therapeutic index (LNM rate multiplied by 3-year overall survival [OS]) was determined to assess the survival benefit of lymphadenectomy.
resultsAmong 449 patients, less than half had LNM (N = 183, 40.8%). The median number of evaluated and metastatic lymph nodes (LNs) was 3 (interquartile range [IQR]: 1-6) and 1 (IQR: 0-1), respectively. 3-year OS among patients with LNM in the entire cohort was 26.8%. The therapeutic index was lower among patients with T4 (5.9) or T1 (6.0) tumors as well as carbohydrate antigen (CA19-9) ≥200 UI/mL (6.0). Of note, a therapeutic index difference ≥10 was noted relative to CA19-9 (<200: 18.7 vs ≥200: 6.0), American Joint Committee on Cancer T Stage (T1: 6.0 vs T2: 17.8 vs T4: 5.9) and number of LNs examined (1-2: 6.9 vs ≥6: 16.9). Concomitant common bile duct resection was not associated with a higher therapeutic index among patients with either T2 or T3 disease.
conclusionCertain clinicopathological factors including T1 or T4 tumor and CA19-9 ≥200 UI/mL were associated with a low therapeutic index. Resection of six or more LNs was associated with a meaningful therapeutic index benefit among patients with LNM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.